{"preliminary_commentary":{"by_channel":{"x_thread":31,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06465069\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-02T18:42:45.188Z","note":"Automated from the 33 newest of 34 indexed sources (Nov 2025 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":33,"text":"- Whether Nectin-4 remains a viable target after EV exposure\n- Whether changing payloads can overcome resistance, including after prior Topo-I ADC exposure\n- How Nectin-4 ADCs should be sequenced after EV or another ADC\n- How CYP2D6 status should guide dosing and toxicity management\n\nAlso discussed: adc development landscape."},"drugs_tested":[["LY4052031"],["LY4052031","pembrolizumab"]],"indication":"advanced or metastatic urothelial carcinoma or solid tumors","name":"NEXUS-01","nct_id":"NCT06465069","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nexus-01-nct06465069. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEXUS-01","arms":[{"description":"Escalating doses of LY4052031 administered intravenously (IV).","label":"LY4052031 (Dose-escalation, Cohort A1)","type":"EXPERIMENTAL"},{"description":"Comparing 2 or more doses (evaluated during dose escalation) of LY4052031 administered IV.","label":"LY4052031 (Dose-optimization, Cohort A2)","type":"EXPERIMENTAL"},{"description":"LY4052031 administered IV.","label":"LY4052031 (Dose-expansion, Cohort B1, B2, C1)","type":"EXPERIMENTAL"},{"description":"LY4052031 administered IV. Pembrolizumab administered IV.","label":"LY4052031+ Pembrolizumab (Dose-expansion, Cohort D)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05","type":"ESTIMATED"},"conditions":["Metastatic Solid Tumor","Recurrent Solid Tumor","Advanced Solid Tumor","Urinary Bladder Neoplasm","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Esophageal Cancer","Pancreatic Cancer","Ovarian Cancer","Cervical Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Cancer","Renal Pelvis Cancer","Bladder Cancer"],"enrollment":{"count":460,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LY4052031","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-22","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031","timeFrame":"Cycle 1 (21 Days)"},{"measure":"Phase 1b: To assess the antitumor activity of LY4052031 as monotherapy or in combination with pembrolizumab: Overall response rate (ORR)","timeFrame":"Up to Approximately 48 Months or 4 Years"}],"references":[],"start_date":{"date":"2024-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06465069"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nexus-01-nct06465069"}